211 related articles for article (PubMed ID: 24951911)
1. [Toxicity of intravesical gemcitabine in superficial bladder cancer treatment].
Beardo Villar P; Gamaza Martínez R; Gavira Moreno R
Farm Hosp; 2014 May; 38(3):249-51. PubMed ID: 24951911
[TBL] [Abstract][Full Text] [Related]
2. Toxic epidermal necrolysis associated with gemcitabine therapy in a patient with metastatic transitional cell carcinoma of the bladder.
Mermershtain W; Cohen AD; Lazarev I; Grunwald M; Ariad S
J Chemother; 2003 Oct; 15(5):510-1. PubMed ID: 14598945
[TBL] [Abstract][Full Text] [Related]
3. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study.
Laufer M; Ramalingam S; Schoenberg MP; Haisfield-Wolf ME; Zuhowski EG; Trueheart IN; Eisenberger MA; Nativ O; Egorin MJ
J Clin Oncol; 2003 Feb; 21(4):697-703. PubMed ID: 12586808
[TBL] [Abstract][Full Text] [Related]
4. Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option.
Gontero P; Marini L; Frea B
BJU Int; 2005 Nov; 96(7):970-6. PubMed ID: 16225511
[No Abstract] [Full Text] [Related]
5. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.
Dalbagni G; Russo P; Sheinfeld J; Mazumdar M; Tong W; Rabbani F; Donat MS; Herr HW; Sogani P; dePalma D; Bajorin D
J Clin Oncol; 2002 Aug; 20(15):3193-8. PubMed ID: 12149290
[TBL] [Abstract][Full Text] [Related]
6. Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability.
Campodonico F; Canepa G; Capponi G; Bozzo L; Maffezzini M
Anticancer Res; 2005; 25(3c):2381-4. PubMed ID: 16080464
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions.
Serretta V; Galuffo A; Pavone C; Allegro R; Pavone-MacAluso M
Urology; 2005 Jan; 65(1):65-9. PubMed ID: 15667865
[TBL] [Abstract][Full Text] [Related]
8. Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study.
Mattioli F; Curotto A; Manfredi V; Gosmar M; Garbero C; Ambruosi C; Carmignani G; Martelli A
Anticancer Res; 2005; 25(3c):2493-6. PubMed ID: 16080482
[TBL] [Abstract][Full Text] [Related]
9. Antineoplastic effect of gemcitabine in an animal model of superficial bladder cancer.
Nativ O; Dalal E; Laufer M; Sabo E; Aronson M
Urology; 2004 Oct; 64(4):845-8. PubMed ID: 15491745
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine in bladder cancer.
El Karak F; Flechon A
Expert Opin Pharmacother; 2007 Dec; 8(18):3251-6. PubMed ID: 18035967
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of the bladder.
Campodonico F; Maffezzini M
Urology; 2005 Nov; 66(5):1141-2; author reply 1142. PubMed ID: 16286156
[No Abstract] [Full Text] [Related]
12. Phase I study of radiochemotherapy with gemcitabine in invasive bladder cancer.
Borut K; Lijana ZK
Radiother Oncol; 2012 Mar; 102(3):412-5. PubMed ID: 21890225
[TBL] [Abstract][Full Text] [Related]
13. PHARMAC's response on gemcitabine and transparency.
Crausaz S; Metcalfe S
N Z Med J; 2005 Nov; 118(1225):U1741. PubMed ID: 16286949
[No Abstract] [Full Text] [Related]
14. Initial experience of intravesical gemcitabine for patients with high-risk superficial transitional cell carcinoma of the bladder following BCG failure.
Allchorne P; Lamb BW; Kinsella J; Shamash J; Green JS
Urol Nurs; 2014; 34(2):95-9. PubMed ID: 24919248
[TBL] [Abstract][Full Text] [Related]
15. Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 3. Photo therapy recall with gemcitabine following ultraviolet B treatment.
Badger J; Kang S; Uzieblo A; Srinivas S
J Clin Oncol; 2005 Oct; 23(28):7224-5. PubMed ID: 16192608
[No Abstract] [Full Text] [Related]
16. Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium.
Bellmunt J; Albiol S; de Olano AR; Pujadas J; Maroto P;
Ann Oncol; 2006 May; 17 Suppl 5():v113-7. PubMed ID: 16807437
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.
Stadler WM; Kuzel T; Roth B; Raghavan D; Dorr FA
J Clin Oncol; 1997 Nov; 15(11):3394-8. PubMed ID: 9363871
[TBL] [Abstract][Full Text] [Related]
18. Intravesical therapy for superficial cancer: need for more options.
Crawford ED
J Clin Oncol; 2002 Aug; 20(15):3185-6. PubMed ID: 12149286
[No Abstract] [Full Text] [Related]
19. Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer.
Palou J; Carcas A; Segarra J; Duque B; Salvador J; Garcia-Ribas I; Villavicencio H
J Urol; 2004 Aug; 172(2):485-8. PubMed ID: 15247710
[TBL] [Abstract][Full Text] [Related]
20. Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation.
De Berardinis E; Antonini G; Peters GJ; Loves WJ; Van der Born K; Codacci-Pisanelli G; Di Silverio F
BJU Int; 2004 Mar; 93(4):491-4. PubMed ID: 15008715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
